Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
University of Utah
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05405387CT.gov Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Budesonide (this asset) | University of Utah | P2 | CC · 47 |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Lenalidomide | National Cancer Institute (NCI) | P3 | B |
| Melphalan | National Cancer Institute (NCI) | P2 | B |
| Dexasone | National Cancer Institute (NCI) | P3 | B |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Daratumumab | National Cancer Institute (NCI) | P3 | B |
| Carfilzomib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Plasma Cell Leukemia cohort
Other indications for Budesonide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Asthma | — | P4 | BBB · 76 |
| Childhood Acute Lymphoblastic Leukemia | — | P4 | B · 58 |
| Primary Biliary Cholangitis | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Budesonide in Plasma Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/budesonide-plasma-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →